May 05, 2025

PDS Updates Continue to Reduce Treatment Burden for Patients with nAMD, DME, and DR

These types of improvements are relatively common after initial approval and are the result of optimization as surgical techniques and knowledge evolve.

Conexiant

April 27, 2025

How to Increase Volume in the Space You Have

It's all about flow, says consultant Larry R. Brooks.

Ophthalmology Management

April 24, 2025

FDA Rejects Extended Dosing Intervals for Eylea HD

The agency did not agree with Regeneron’s proposal to add dosing intervals greater than every 16 weeks, the maximum interval currently indicated for aflibercept 8 mg injections.

Retinal Physician

April 18, 2025

Improvements in OCT Imaging Performance, Processing, and Analysis 

“We can expect instruments to continue to improve as hardware does, and image analysis techniques to improve as more powerful machine learning algorithms are introduced,” study authors wrote.

Conexiant

April 16, 2025

Biocon, Regeneron Reach Agreement on Eylea Biosimilar

The agreement clears the way for Yesafili, an FDA-approved aflibercept biosimilar, to be commercialized in the United States.

Retinal Physician

September 18, 2024

Assessing the Impact of iRORA Lesions on Retina Sensitivity and Function

A new case study explores the impact of incomplete retinal pigment epithelium and outer retinal atrophy lesions on retinal sensitivity in intermediate age-related macular degeneration, shedding light on potential surrogate markers for retinal dysfunction. (Source: BMJ Open Ophthalmology)

Conexiant

February 13, 2025

FDA Approves Extended Label for Avacincaptad Pegol

The new label removes limitations on the duration of dosing.

Conexiant

January 16, 2025

LA County Fires Prompt Business Recovery Centers to Open

"Business owners can meet face-to-face with specialists to apply for disaster loans and access a wide range of resources to guide them through their recovery."

Optometric Management

January 22, 2025

High, Low HDLs Tied to AMD Risk

The lack of association between LDLs and triglycerides and AMD risk “suggests that plasma HDL specifically may play a role in progression to early and intermediate AMD.”

Conexiant